Indium-111 labeled leukocytes in evaluation of active specific immunotherapy responses

L. P. Kasi, L. M. Lamki, S. Saranti, D. A. Podoloff

Research output: Contribution to journalArticle

Abstract

Active immunization of patients utilizing viral oncolysates (VO) has been studied in clinical trials. VO are extracts of cultured tumor cells that have been infected with certain types of viruses, particularly surface budding varieties. The objectives of the current studies were to examine the trafficking patterns of Indium (In)-111-labeled leukocytes or lymphocytes in two groups of patients with gynecologic malignancies to determine whether these cells migrate to sites of active immunization after VO. Eight patients with ovarian cancer received VO intraperitoneally followed by In-Ill-labeled leukocytes or lymphocytes (500 µCi) intravenously. In a separate trial, three patients with cervical cancer received In-Ill-labeled lymphocytes after they had been treated with VO administered by the intralymphatic route. Gamma camera imaging was performed to evaluate the distribution patterns of the labeled cells at several time intervals after injection. Results indicate that metastatic tumor sites exposed to VO therapy show significant uptake of In-111 cells. These sites of malignancies were confirmed by computerized tomography and ultrasound scans. In patients with ovarian cancer no uptake of the radiolabeled cells was observed in metastatic tumors of the liver and lymph nodes. In patients with cervical cancer, lymph node metastases exposed to intralymphatic VO therapy were visualized very well. Other known tumor sites not exposed to VO therapy showed no uptake of radioactivity. These findings confirm that VO induces immune responses. This diagnostic nuclear medicine technique may prove to be a useful method for following-up responses to immunotherapy.

Original languageEnglish
Pages (from-to)226-232
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume5
Issue number3
Publication statusPublished - 1995

Fingerprint

Active Immunotherapy
Indium
Leukocytes
Lymphocytes
Neoplasms
Uterine Cervical Neoplasms
Ovarian Neoplasms
Vaccination
Lymph Nodes
Cultured Tumor Cells
Nuclear Medicine
Radionuclide Imaging
Immunotherapy
Radioactivity
Therapeutics
Tomography
Clinical Trials
Neoplasm Metastasis
Viruses
Injections

Keywords

  • Biological response modifiers
  • In-111 leukocytes
  • In-111 lymphocytes
  • Ovarian cancer
  • Uterine cervical cancer
  • Viral oncolysate

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Indium-111 labeled leukocytes in evaluation of active specific immunotherapy responses. / Kasi, L. P.; Lamki, L. M.; Saranti, S.; Podoloff, D. A.

In: International Journal of Gynecological Cancer, Vol. 5, No. 3, 1995, p. 226-232.

Research output: Contribution to journalArticle

@article{f9e7f7b0886747a091430ad78082a96b,
title = "Indium-111 labeled leukocytes in evaluation of active specific immunotherapy responses",
abstract = "Active immunization of patients utilizing viral oncolysates (VO) has been studied in clinical trials. VO are extracts of cultured tumor cells that have been infected with certain types of viruses, particularly surface budding varieties. The objectives of the current studies were to examine the trafficking patterns of Indium (In)-111-labeled leukocytes or lymphocytes in two groups of patients with gynecologic malignancies to determine whether these cells migrate to sites of active immunization after VO. Eight patients with ovarian cancer received VO intraperitoneally followed by In-Ill-labeled leukocytes or lymphocytes (500 µCi) intravenously. In a separate trial, three patients with cervical cancer received In-Ill-labeled lymphocytes after they had been treated with VO administered by the intralymphatic route. Gamma camera imaging was performed to evaluate the distribution patterns of the labeled cells at several time intervals after injection. Results indicate that metastatic tumor sites exposed to VO therapy show significant uptake of In-111 cells. These sites of malignancies were confirmed by computerized tomography and ultrasound scans. In patients with ovarian cancer no uptake of the radiolabeled cells was observed in metastatic tumors of the liver and lymph nodes. In patients with cervical cancer, lymph node metastases exposed to intralymphatic VO therapy were visualized very well. Other known tumor sites not exposed to VO therapy showed no uptake of radioactivity. These findings confirm that VO induces immune responses. This diagnostic nuclear medicine technique may prove to be a useful method for following-up responses to immunotherapy.",
keywords = "Biological response modifiers, In-111 leukocytes, In-111 lymphocytes, Ovarian cancer, Uterine cervical cancer, Viral oncolysate",
author = "Kasi, {L. P.} and Lamki, {L. M.} and S. Saranti and Podoloff, {D. A.}",
year = "1995",
language = "English",
volume = "5",
pages = "226--232",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Indium-111 labeled leukocytes in evaluation of active specific immunotherapy responses

AU - Kasi, L. P.

AU - Lamki, L. M.

AU - Saranti, S.

AU - Podoloff, D. A.

PY - 1995

Y1 - 1995

N2 - Active immunization of patients utilizing viral oncolysates (VO) has been studied in clinical trials. VO are extracts of cultured tumor cells that have been infected with certain types of viruses, particularly surface budding varieties. The objectives of the current studies were to examine the trafficking patterns of Indium (In)-111-labeled leukocytes or lymphocytes in two groups of patients with gynecologic malignancies to determine whether these cells migrate to sites of active immunization after VO. Eight patients with ovarian cancer received VO intraperitoneally followed by In-Ill-labeled leukocytes or lymphocytes (500 µCi) intravenously. In a separate trial, three patients with cervical cancer received In-Ill-labeled lymphocytes after they had been treated with VO administered by the intralymphatic route. Gamma camera imaging was performed to evaluate the distribution patterns of the labeled cells at several time intervals after injection. Results indicate that metastatic tumor sites exposed to VO therapy show significant uptake of In-111 cells. These sites of malignancies were confirmed by computerized tomography and ultrasound scans. In patients with ovarian cancer no uptake of the radiolabeled cells was observed in metastatic tumors of the liver and lymph nodes. In patients with cervical cancer, lymph node metastases exposed to intralymphatic VO therapy were visualized very well. Other known tumor sites not exposed to VO therapy showed no uptake of radioactivity. These findings confirm that VO induces immune responses. This diagnostic nuclear medicine technique may prove to be a useful method for following-up responses to immunotherapy.

AB - Active immunization of patients utilizing viral oncolysates (VO) has been studied in clinical trials. VO are extracts of cultured tumor cells that have been infected with certain types of viruses, particularly surface budding varieties. The objectives of the current studies were to examine the trafficking patterns of Indium (In)-111-labeled leukocytes or lymphocytes in two groups of patients with gynecologic malignancies to determine whether these cells migrate to sites of active immunization after VO. Eight patients with ovarian cancer received VO intraperitoneally followed by In-Ill-labeled leukocytes or lymphocytes (500 µCi) intravenously. In a separate trial, three patients with cervical cancer received In-Ill-labeled lymphocytes after they had been treated with VO administered by the intralymphatic route. Gamma camera imaging was performed to evaluate the distribution patterns of the labeled cells at several time intervals after injection. Results indicate that metastatic tumor sites exposed to VO therapy show significant uptake of In-111 cells. These sites of malignancies were confirmed by computerized tomography and ultrasound scans. In patients with ovarian cancer no uptake of the radiolabeled cells was observed in metastatic tumors of the liver and lymph nodes. In patients with cervical cancer, lymph node metastases exposed to intralymphatic VO therapy were visualized very well. Other known tumor sites not exposed to VO therapy showed no uptake of radioactivity. These findings confirm that VO induces immune responses. This diagnostic nuclear medicine technique may prove to be a useful method for following-up responses to immunotherapy.

KW - Biological response modifiers

KW - In-111 leukocytes

KW - In-111 lymphocytes

KW - Ovarian cancer

KW - Uterine cervical cancer

KW - Viral oncolysate

UR - http://www.scopus.com/inward/record.url?scp=0028955062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028955062&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 226

EP - 232

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 3

ER -